RxDoctor Payments DataLook up a doctor →

William Zweig, MD

Pulmonary Disease · Saint Louis, MONPI 1043201205

Payments from drug & device makers

$18,706in general payments, 2019–2025

Across 999 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$889
  • Insmed, Inc.$870
  • plus $8K from 47 others

What the payments were for

  • Food & beverage$18,10797%
  • Education$5983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,706 in reported general payments places this provider in the 80th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$174,118
Medicare patients
624
Services billed
1,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate83$1,056,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter422$331,937
Tyvaso DpiTreprostinil13$307,580
NucalaMepolizumab58$230,013
WakixPitolisant Hcl12$176,092
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr199$107,830
Breo ElliptaFluticasone/Vilanterol228$105,693
XolairOmalizumab24$84,792
Dupixent PenDupilumab13$53,654
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$46,835
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$24,771
Incruse ElliptaUmeclidinium Bromide37$17,883
Spiriva RespimatTiotropium Bromide22$15,791
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate55$12,640
EliquisApixaban11$10,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$2,050$1,097,328145 claims
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$2,844$793,356944 claims
Harmony Biosciences LLCWakix$373$176,09212 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,691$62,107109 claims
PfizerEliquis$80$10,73111 claims
SandozEnoxaparin Sodium$22$8,67812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →